Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High - Here's Why

Key Points

• Pulse Biosciences shares hit a new 52-week high of $48.10 before trading at $46.00, despite closing down 1.7% and remaining well above its 50-day and 200-day moving averages.
• Analyst sentiment is broadly positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $45.25 average price target. Needham initiated coverage with a Buy rating and a $58 target, while Canaccord raised its target to $43.
• The company continues to report weak financial results, including a quarterly EPS loss of $0.36 versus the expected $0.29 loss and revenue of $0.43 million versus $0.53 million expected. Institutional investors own approximately 76.95% of the stock.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $48.10 and last traded at $46.00, with a volume of 525728 shares trading hands. The stock had previously closed at $46.79.

Analyst Upgrades and Downgrades

PLSE has been the subject of a number of research analyst reports. Needham & Company LLC began coverage on shares of Pulse Biosciences in a research note on Monday. They issued a "buy" rating and a $58.00 target price for the company. Mizuho set a $45.00 price target on Pulse Biosciences in a research note on Monday, August 10th. Canaccord Genuity Group boosted their price target on Pulse Biosciences from $32.00 to $43.00 and gave the company a "buy" rating in a report on Monday, August 10th. Wall Street Zen cut Pulse Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Pulse Biosciences in a report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pulse Biosciences has an average rating of "Moderate Buy" and a consensus price target of $45.25.

Pulse Biosciences Trading Down 1.7%

The firm's 50 day simple moving average is $31.70 and its 200-day simple moving average is $25.20. The stock has a market capitalization of $3.18 billion, a price-to-earnings ratio of -38.98 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. As a group, equities research analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its holdings in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock worth $26,000 after buying an additional 680 shares during the last quarter. Osterweis Capital Management Inc. bought a new position in shares of Pulse Biosciences in the 2nd quarter valued at about $28,000. Tower Research Capital LLC TRC grew its position in shares of Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after acquiring an additional 2,156 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock worth $70,000 after purchasing an additional 619 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Pulse Biosciences during the 2nd quarter worth about $158,000. Institutional investors and hedge funds own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source